BONEX — BoneSupport Holding AB Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid CapNeutral
- SEK5.53bn
- SEK5.34bn
- SEK328.82m
Annual income statement for BoneSupport Holding AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 96.6 | 155 | 181 | 213 | 329 |
| Cost of Revenue | |||||
| Gross Profit | 81.5 | 136 | 162 | 190 | 298 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 271 | 314 | 279 | 294 | 393 |
| Operating Profit | -174 | -158 | -98.6 | -80.7 | -64.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -175 | -158 | -99 | -81.8 | -64.7 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -176 | -161 | -101 | -85.5 | -68.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -176 | -161 | -101 | -85.5 | -68.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -176 | -161 | -101 | -85.5 | -68.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.46 | -3.1 | -1.72 | -1.34 | -1.06 |
| Dividends per Share |